Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David McDonnell

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|July 2, 2014
David McDonnell: Time for NLP to be part of mainstream GP consultation teaching?David McDonnell
Diabetic Medicine : a Journal of the British Diabetic Association|June 20, 2024
Letter to the editorDavid McDonnell, Diarmuid Smith, Hannah Forde
Clinical Therapeutics|October 24, 2018
Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with SchizophreniaLei Sun, David McDonnell, Lisa von Moltke
Pharmacoeconomics|November 11, 2022
Comment on "An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia"Bhaskar Rege, James McGrory, Sabina Gasper, et al.
BMJ Case Reports|November 25, 2017
Eosinophilic myocarditis as a first presentation of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)Ronan Bluett, David McDonnell, Claire O'Dowling, et al.
Clinical Pharmacology in Drug Development|March 29, 2019
Effect of Food on the Pharmacokinetics of a Combination of Olanzapine and SamidorphanLei Sun, David McDonnell, Jianjun Liu, et al.
Clinical Pharmacology in Drug Development|July 31, 2018
Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine-Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability StudyLei Sun, David McDonnell, Jianjun Liu, et al.
International Clinical Psychopharmacology|October 16, 2010
Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switchingHolland C Detke, Fangyi Zhao, Parag Garhyan, et al.
Clinical Drug Investigation|March 20, 2019
A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human SubjectsLei Sun, David McDonnell, Miao Yu, et al.
CNS Spectrums|May 13, 2020
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension studySergey Yagoda, Christine Graham, Adam Simmons, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|July 2, 2014
David McDonnell: Time for NLP to be part of mainstream GP consultation teaching?David McDonnell
Diabetic Medicine : a Journal of the British Diabetic Association|June 20, 2024
Letter to the editorDavid McDonnell, Diarmuid Smith, Hannah Forde
Clinical Therapeutics|October 24, 2018
Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with SchizophreniaLei Sun, David McDonnell, Lisa von Moltke
Pharmacoeconomics|November 11, 2022
Comment on "An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia"Bhaskar Rege, James McGrory, Sabina Gasper, et al.
BMJ Case Reports|November 25, 2017
Eosinophilic myocarditis as a first presentation of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)Ronan Bluett, David McDonnell, Claire O'Dowling, et al.
Clinical Pharmacology in Drug Development|March 29, 2019
Effect of Food on the Pharmacokinetics of a Combination of Olanzapine and SamidorphanLei Sun, David McDonnell, Jianjun Liu, et al.
Clinical Pharmacology in Drug Development|July 31, 2018
Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine-Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability StudyLei Sun, David McDonnell, Jianjun Liu, et al.
International Clinical Psychopharmacology|October 16, 2010
Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switchingHolland C Detke, Fangyi Zhao, Parag Garhyan, et al.
Clinical Drug Investigation|March 20, 2019
A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human SubjectsLei Sun, David McDonnell, Miao Yu, et al.
CNS Spectrums|May 13, 2020
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension studySergey Yagoda, Christine Graham, Adam Simmons, et al.
Pageof 4